Drug intelligence / Profile preview

N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine is a synthetic small molecule belonging to the class of leucine derivatives, specifically an L-peptide linking compound. It features a dodecanoic acid chain with an imidazole group at the omega position, conjugated to L-leucine. This compound has been studied as an inhibitor of cytochrome P450 BM3 (CYP102A1), a bacterial P450 enzyme from Bacillus megaterium. Structural studies show it binds to the heme domain of P450BM3 and acts as a more potent inhibitor than parent omega-imidazolyl fatty acids, likely due to its unique interaction with the enzyme's active site. Its pharmacological action in humans is unknown and it has not been approved for any clinical use[6][9][5].

Other names
N-(12-(1H-imidazol-1-yl)dodecanoyl)-L-leucine(2S)-2-(12-(1H-imidazol-1-yl)dodecanamido)-4-methylpentanoic acid(2S)-2-[12-(1H-imidazol-1-yl)dodecanamido]-4-methylpentanoic acidN-[12-(1h-Imidazol-1-Yl)dodecanoyl]-L-LeucineN-[12-(Imidazolyl)-dodecanoyl]-L-leucine
02

Targets

CYP102A1 (Cytochrome P450 BM3)

Beyond the preview

Go deeper on N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call